mlpa Search Results


ms-mlpa reagents kits  (MRC-Holland)
90
MRC-Holland ms-mlpa reagents kits
Ms Mlpa Reagents Kits, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/ms+mlpa+kit/ppr0406203-44-2-10
Average 90 stars, based on 1 article reviews
ms-mlpa reagents kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
commercial multiplex ligation-dependent probe amplification (mlpa) kits  (MRC-Holland)
90
MRC-Holland commercial multiplex ligation-dependent probe amplification (mlpa) kits
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Commercial Multiplex Ligation Dependent Probe Amplification (Mlpa) Kits, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/multiplex+ligation+dependent+probe+amplification++mlpa/pmc05721229-136-10-23
Average 90 stars, based on 1 article reviews
commercial multiplex ligation-dependent probe amplification (mlpa) kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
salsa mlpa p051 parkinson mix 1 probemix  (MRC-Holland)
90
MRC-Holland salsa mlpa p051 parkinson mix 1 probemix
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Salsa Mlpa P051 Parkinson Mix 1 Probemix, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/p051+salsa+mlpa+parkinson+probe+set/pmc04592918-71-21-36
Average 90 stars, based on 1 article reviews
salsa mlpa p051 parkinson mix 1 probemix - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
p158 mlpa kit  (MRC-Holland)
90
MRC-Holland p158 mlpa kit
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
P158 Mlpa Kit, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/p158+mlpa+kit/pmc03513537-80-17-20
Average 90 stars, based on 1 article reviews
p158 mlpa kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mlpa scn1a kit (salsa p137 version a2; mrcholland, amsterdam, the netherlands)  (MRC-Holland)
90
MRC-Holland mlpa scn1a kit (salsa p137 version a2; mrcholland, amsterdam, the netherlands)
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Mlpa Scn1a Kit (Salsa P137 Version A2; Mrcholland, Amsterdam, The Netherlands), supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/mlpa+scn1a+kit++salsa+p137+version+a2++mrcholland++amsterdam++the+netherlands+/pm21204810-43-1-8
Average 90 stars, based on 1 article reviews
mlpa scn1a kit (salsa p137 version a2; mrcholland, amsterdam, the netherlands) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mlpa  (FALCO Biosystems Ltd)
90
FALCO Biosystems Ltd mlpa
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Mlpa, supplied by FALCO Biosystems Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/mlpa/pm22011817-34-0-4
Average 90 stars, based on 1 article reviews
mlpa - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ms-mlpa probe set  (MRC-Holland)
90
MRC-Holland ms-mlpa probe set
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Ms Mlpa Probe Set, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/ms+mlpa+probe+set/pmc03070573-65-10-14
Average 90 stars, based on 1 article reviews
ms-mlpa probe set - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mlpa probes  (MRC-Holland)
90
MRC-Holland mlpa probes
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Mlpa Probes, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/mlpa+probes/pm34811950-103-0-8
Average 90 stars, based on 1 article reviews
mlpa probes - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
salsa mlpa p219-b2 pax6 probes  (MRC-Holland)
90
MRC-Holland salsa mlpa p219-b2 pax6 probes
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Salsa Mlpa P219 B2 Pax6 Probes, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/salsa+mlpa+p219+pax6+kit/pmc07499969-36-52-58
Average 90 stars, based on 1 article reviews
salsa mlpa p219-b2 pax6 probes - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
kit salsa p250 for dgs/vcfs  (MRC-Holland)
90
MRC-Holland kit salsa p250 for dgs/vcfs
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Kit Salsa P250 For Dgs/Vcfs, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/mlpa+salsa+p250+digeorge+diagnostic+probe+kit/pmc03776404-41-4-5
Average 90 stars, based on 1 article reviews
kit salsa p250 for dgs/vcfs - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
p474 mlpa kit  (MRC-Holland)
90
MRC-Holland p474 mlpa kit
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
P474 Mlpa Kit, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/p474+mlpa+kit/pm39179669-50-23-26
Average 90 stars, based on 1 article reviews
p474 mlpa kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
salsa ® mlpa ® probemix p050-c1 cah  (MRC-Holland)
90
MRC-Holland salsa ® mlpa ® probemix p050-c1 cah
<t>Somatic</t> <t>TP53</t> mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.
Salsa ® Mlpa ® Probemix P050 C1 Cah, supplied by MRC-Holland, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mlpa/mlpa+kit/pmc08540623-137-18-25
Average 90 stars, based on 1 article reviews
salsa ® mlpa ® probemix p050-c1 cah - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Somatic TP53 mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.

Journal: Journal of Clinical Oncology

Article Title: Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study

doi: 10.1200/JCO.2017.74.2460

Figure Lengend Snippet: Somatic TP53 mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of acquired TP53 mutations. (B) Kaplan-Meier estimates for progression-free survival (B) in pediatric patients with ACTs with or without acquired TP53 mutations and (C) by TP53 status and disease stage. After discriminating for disease stage and including stage IV disease in the Cox regression model, presence of somatic TP53 mutations was no longer associated with outcome (P = .21). hom, homozygous.

Article Snippet: Large deletions of TP53 and ATRX were assessed using commercial multiplex ligation-dependent probe amplification (MLPA) kits (PO56 TP53 probemix and P013 ATRX probemix; MRC-Holland, Amsterdam, the Netherlands) as per manufacturer instructions.

Techniques:

Somatic CTNNB1 mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of activating CTNNB1 mutations. (B) Immunohistochemical analysis of β-catenin and yes-associated protein 1 (YAP1) in pediatric ACTs. YAP serves as a surrogate marker for β-catenin expression. Moderate nuclear immunostaining of (i) β-catenin and (ii) YAP in a tumor with the S45P mutation in CTNNB1. Strong nuclear immunoreactivity for (iii) β-catenin and (iv) YAP in a pediatric patient with unknown CTNNB1 molecular status. These results are indicative of Wnt signaling pathway activation. Size bars represent 50 μm. (C) Kaplan-Meier estimates for progression-free survival by CTNNB1 status (P = .80).

Journal: Journal of Clinical Oncology

Article Title: Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study

doi: 10.1200/JCO.2017.74.2460

Figure Lengend Snippet: Somatic CTNNB1 mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of activating CTNNB1 mutations. (B) Immunohistochemical analysis of β-catenin and yes-associated protein 1 (YAP1) in pediatric ACTs. YAP serves as a surrogate marker for β-catenin expression. Moderate nuclear immunostaining of (i) β-catenin and (ii) YAP in a tumor with the S45P mutation in CTNNB1. Strong nuclear immunoreactivity for (iii) β-catenin and (iv) YAP in a pediatric patient with unknown CTNNB1 molecular status. These results are indicative of Wnt signaling pathway activation. Size bars represent 50 μm. (C) Kaplan-Meier estimates for progression-free survival by CTNNB1 status (P = .80).

Article Snippet: Large deletions of TP53 and ATRX were assessed using commercial multiplex ligation-dependent probe amplification (MLPA) kits (PO56 TP53 probemix and P013 ATRX probemix; MRC-Holland, Amsterdam, the Netherlands) as per manufacturer instructions.

Techniques: Immunohistochemical staining, Marker, Expressing, Immunostaining, Mutagenesis, Activation Assay

(A) Hematoxylin and eosin staining and Ki-67 labeling index (LI) in pediatric adrenocortical tumors without TP53 mutations: (i, ii) tumor with a high (≥ 15%) Ki-67 labeling index (LI; red arrows indicate mitotic figures), (iii, iv) tumor with a low (< 5%) LI. Size bars represent 50 μm. (B) Kaplan-Meier estimates for progression-free survival (PFS) according to Ki-67 LI showing that Ki-67 LI < 15% was significantly associated with longer PFS (P = .002). (C) Kaplan-Meier estimates for PFS according to Ki-67 LI and disease stage. Ki-67 LI remained significantly associated with outcome after adjusting for disease stage (P = .0048).

Journal: Journal of Clinical Oncology

Article Title: Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study

doi: 10.1200/JCO.2017.74.2460

Figure Lengend Snippet: (A) Hematoxylin and eosin staining and Ki-67 labeling index (LI) in pediatric adrenocortical tumors without TP53 mutations: (i, ii) tumor with a high (≥ 15%) Ki-67 labeling index (LI; red arrows indicate mitotic figures), (iii, iv) tumor with a low (< 5%) LI. Size bars represent 50 μm. (B) Kaplan-Meier estimates for progression-free survival (PFS) according to Ki-67 LI showing that Ki-67 LI < 15% was significantly associated with longer PFS (P = .002). (C) Kaplan-Meier estimates for PFS according to Ki-67 LI and disease stage. Ki-67 LI remained significantly associated with outcome after adjusting for disease stage (P = .0048).

Article Snippet: Large deletions of TP53 and ATRX were assessed using commercial multiplex ligation-dependent probe amplification (MLPA) kits (PO56 TP53 probemix and P013 ATRX probemix; MRC-Holland, Amsterdam, the Netherlands) as per manufacturer instructions.

Techniques: Staining, Labeling

Characteristics of Patients With ACTs Harboring Mutations or No Mutations in TP53

Journal: Journal of Clinical Oncology

Article Title: Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study

doi: 10.1200/JCO.2017.74.2460

Figure Lengend Snippet: Characteristics of Patients With ACTs Harboring Mutations or No Mutations in TP53

Article Snippet: Large deletions of TP53 and ATRX were assessed using commercial multiplex ligation-dependent probe amplification (MLPA) kits (PO56 TP53 probemix and P013 ATRX probemix; MRC-Holland, Amsterdam, the Netherlands) as per manufacturer instructions.

Techniques: